Dr. Animesh Saha-Radiation Oncologist

Dr. Animesh Saha

MBBS, MD, DNB (Radiotherapy)

Radiation Oncologist

Practice Location of Dr. Animesh Saha

58, Canal Circular Road,

Kankurgachi, Kolkata

Get Directions
OP Timings
On Call

Fee: 1000

  • Practice Locations (1)

  • Profile

  • Patient Reviews

  • Q&A


  • Radiation Oncologist


  • MBBS - R G Kar Medical College and Hospital - 2009 - Kolkata
  • MD - Radiotherapy - West Bengal State University - 2013 - Kolkata
  • DNB - Radiotherapy - National Board of Examinations - 2014 - Kolkata
  • Fellow of the Royal College of Radiologists - RCR - 2018 - London
  • CESR - General Medical Council - UK


  • Specialist Registrar Leeds Cancer Centre - NHS Trust - UK - 2017 - 2018
  • Consultant Clinical Oncologist Leeds Cancer Centre - NHS Trust - UK - 2018 - 2019
  • Consultant Clinical Oncologist Apollo Multispeciality Hospital - Kankurgachi - 2019 - Currently Working


  • 64647 West Bengal Medical Council 2009

Awards and Recognitions

  • Certificate of Eligibility for Specialist Registration (CESR), UK Awarded by General Medical Council, UK in October - 2019
  • Cyclotron Trust Award with Travel Grant to Attend the Education Sessions of PTCOG-58 Conference held in Manchester , United Kingdom
  • Having Qualified for the Award of Diplomate of the National Board of Examinations in Radiotherapy at the Examination held in December, 2013; has been Admitted by the Council as Member (MNAMS) of the National Academy of Medical Sciences (India) in the year 2018
  • FRCR in Clinical Oncology Awarded by Royal College of Radiologists in April,2018
  • Achievements :
  • International training fellowship in St James University Hospital (Leeds teaching hospital), UK from March 2017- October 2018.
  • Fellowship in Clinical oncology from Tata Medical Center, Kolkata, India from June - 2013 to January - 2017
  • He was selected for ESMO preceptorship on Brain tumor held between September 28, 2018-September 29, 2018 in Athens, Greece.
  • Hypo-fractionated radiotherapy schedule of 35Gy in 10 Fractions in advanced incurable breast cancer: a prospective Phase I/II study (HYPORT study). He got first prize for poster presentation in controversies in Clinical Oncology, which was held in Kolkata, India in 2016
  • Oral Presentation in the Royal College of Radiologists Proffered Paper Session in NCRI Conference 2015, Liverpool, UK; for which He got ‘The Company of Biologists Travel Award’
  • ‘Is Daily MVCT Imaging Really required in helical tomotherapy for head and neck cancers? : An analysis of a large dataset of 2858 fractions’. He had presented this research work in AROICON West Bengal chapter 2013 in Kolkata,India.


  • Indian Medical Association (IMA)
  • Association of Radiation Oncologists of India (AROI)
  • National Academy of Medical Sciences
  • Indian Society of Neuro-Oncology (ISNO)
  • European Society of Medical Oncology (ESMO)
  • European Society for Radiotherapy & Oncology (ESTRO)
  • Indian Society of Oncology (ISO)
  • Royal College of Physicians (UK)

Paper Presentations

  • A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789)
  • Addition of Stereotactic Body Radiotherapy to Systemic Chemotherapy in Locally Advanced Biliary Tract Cancers (ABC07 trial)
  • A Randomised Trial of Conventional Care Versus Radioablation (Stereotactic Body Radiotherapy) for Extracranial Oligometastases (CORE trial)
  • ETOP/IFCT 4-12 STIMULI Trial which is an Open-label, Randomised, Two-Arm, Phase II trial Looking into Addition of Immunotherapy with Nivolumab and Ipilumumab to Standard of Care in Limited Stage Small Cell Lung Carcinoma
  • A Randomized, Phase 3 Trial with Anti-PD-1 Monoclonal Antibody Pembrolizumab (MK-3475) Versus Placebo for Patients with Early Stage NSCLC after Resection and Completion of Standard Adjuvant Therapy (PEARLS)
  • GO40241 Phase III Randomized, Double-Blind, Placebo-Controlled Study (Neoadjuvant early stage resectable NSCLC) –Impower030 trial.
  • Stereotactic Ablative Radiotherapy for Oligometastatic Non-small Cell Lung Cancer: A Randomised Phase III Trial (SARON study)
  • A Multi-Centre Randomised Study of Induction Chemotherapy followed by Capecitabine(+/-nelfinavir) with High or Standard Dose Radiotherapy for Locally Advanced Nonmetastatic Pancreatic Cancer (SCALOP 2 study)
  • A Randomised Phase II trial of Standard Versus Dose Escalated Radiotherapy in the Treatment of Pain in Malignant Pleural Mesothelioma (SYSTEM 2 trial)
  • A Phase 2 Trial of Pembrolizumab (MK-3475) in Combination with Platinum Doublet Chemotherapy and Radiotherapy for Participants with Unresectable, Locally Advanced Stage III Non-Small Cell Lung Cancer (NSCLC) (KEYNOTE-799)
  • A Phase 3 Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) with or without Lenvatinib (E7080/MK-7902) as First-line Intervention in Participants with Metastatic Nonsquamous Non-small Cell Lung Cancer (LEAP-006)
  • Adjuvant Durvalumab/placebo following SABR for stage I/II medically inoperable NSCLC (PACIFIC 4 study)
  • Adjuvant Durvalumab following Sequential Chemotherapy and Radiotherapy in Patients with Unresecatble Stage III NSCLC (PACIFIC 6 study)

Report an error

Patient Reviews for Dr. Animesh Saha

No feedback

No feedback available for this Doctor.
Be the first to write a review.

Question & Answers by Dr. Animesh Saha

No Questions

No Question & Answers by this doctor.